Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208 (b)(3)

John Edwards, Jr., M.D.

Committees:	Anti-Infective Drugs Advisory Comp Drug Safety and Risk Management A	
Meeting Dates:	December 14-15, 2006	
I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the overall benefit to risk considerations for the approved product, Ketek (telithromycin), new drug application (NDA) 21-144, manufactured by Sanofi-Aventis with the current indications of acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community acquired pneumonia, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).		
Type of Interest	Nature	Magnitude
Related Consulting	Competing Firm	Less than \$10,001 per year
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.		
/s/_ Signature of SGE	<u> </u>	_ <u>11/13/06</u> Date